Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3938423 | Fertility and Sterility | 2014 | 12 Pages |
Abstract
Questions as to whether the drug on trial is truly superior to the best available drug or of its cost-benefit profile are overlooked in most cases. There seems to be a deluge of “me-too” drugs with equivocal superiority over existing drugs and cost-benefit profiles. Because clinical trials are time-consuming, no blockbuster drug for endometriosis seems to be on the horizon yet.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Sun-Wei Ph.D.,